Medigene AG Medigene AG

Medigene AG

MDG1

Rank in Stocks #35256
Medigene AG is a German biotechnology company primarily focused on innovating T... Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Universitรฉ de Montrรฉal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
Share Price
$0.14942078
Last synced: 2025-05-15
Market Cap
$3.86M
Change (1 day)
0.10%
Change (1 year)
47.84%
Country
DE
Trade Medigene AG (MDG1)

Category

Healthcare
Stock price history for Medigene AG (MDG1)
Highest end of day price: $0.34 on 2025-04-01

Lowest end of day price: $61.30 on 2007-12-01
Stock price history of Medigene AG from 2007 to 2026
Annual Stock Price Performance
Year Performance
2025 -69.63%
2024 -62.74%
2023 -33.26%
2022 -26.38%
2021 -24.98%
2020 -21.07%
2019 -42.42%
2018 -38.07%
2017 37.11%
2016 29.60%
2015 57.57%
2014 2.53%
2013 -8.47%
2012 -42.08%
2010 -54.73%
2009 -11.17%
2008 -21.76%
2007 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$534.12 25.25%
US
$231.12 760.78%
US
$137.83 -3.78%
AU
$880.75 8.18%
NL
$289.51 1.72%
BE